Current Neuro-Oncology
Volume
24 Number 7
15 April 2022
Home > Publications > Current Neuro-Oncology > Volume 24, Year 2022 > Number 7, 15 April
Eckstein
OS, Allen CE, Williams PM, Roy-Chowdhuri S, Patton DR, Coffey B,
Reid JM, Piao J, Saguilig L, Alonzo TA, Berg SL, Ramirez NC, Jaju
A, Mhlanga J, Fox E, Hawkins DS, Mooney MM, Takebe N, Tricoli JV,
Janeway KA, Seibel NL, Parsons DW.
Phase
II Study of Selumetinib in Children and Young Adults With
Tumors
Harboring Activating Mitogen-Activated Protein Kinase Pathway
Genetic
Alterations:
Arm E of the NCI-COG Pediatric MATCH Trial.
J
Clin Oncol. 2022 Apr 1;40(20):2235-2245∟.
doi: 10.1200/JCO.21.02840∟.
PMID: 35363510∟.
Interventional study˰ ˍ
Guan
Y, Li J, Gong X, Zhu H, Li C, Mei G, Liu X, Pan L, Dai J, Wang Y,
Wang E, Liu Y, Wang X.
Safety
and Efficacy of Hypofractionated Stereotactic
Radiotherapy
with Anlotinib Targeted Therapy for Glioblastoma at the First
Recurrence:
A Preliminary Report.
Brain
Sci. 2022 Apr 2;12(4):471∟.
doi: 10.3390/brainsci12040471∟.
PMID: 35448002∟.
Observational study. ˍ
Galanis
E, Anderson SK, Twohy E, Butowski NA, Hormigo A, Schiff D, Omuro
A, Jaeckle KA, Kumar S, Kaufmann TJ, Geyer S, Kumthekar PU,
Campian J, Giannini C, Buckner JC, Wen PY.
Phase
I/randomized phase II trial of TRC105 plus bevacizumab versus
bevacizumab in recurrent glioblastoma: North Central Cancer
Treatment Group N1174 (Alliance).
Neurooncol
Adv. 2022 Apr 4;4(1):vdac041∟.
doi: 10.1093/noajnl/vdac041∟.
PMID: 35664553∟.
Interventional study. ˍ
Narita
Y, Okita Y, Arakawa Y.
Evaluation
of the efficacy and safety of TAS0313 in adults with recurrent
glioblastoma.
Cancer
Immunol Immunother. 2022 Apr 4∟.
doi: 10.1007/s00262-022-03184-7∟.
PMID: 35377001∟.
Interventional study. ˍ
Wang
X, Zhang Y, Li ZY, Bao JF.
Glioblastoma
in lateral ventricle: A case
report.
Asian
J Surg. 2022 Apr 4;45(8):1648-1649∟.
doi: 10.1016/j.asjsur.2022.03.070∟.
PMID: 35393221∟.
Case report. ˍ
Chen
B, Chen C, Zhao Y, Cui W, Xu J.
The
role of chemotherapy in the
treatment
of adult medulloblastoma.
World
Neurosurg. 2022 Apr 6;163:e435-e449∟.
doi: 10.1016/j.wneu.2022.04.004∟.
PMID: 35398321∟.
Observational study˰ ˍ
de
Groot JF, Kim AH, Prabhu S, Rao G, Laxton AW, Fecci PE, O'Brien
BJ, Sloan A, Chiang V, Tatter SB, Mohammadi AM, Placantonakis DG,
Strowd RE, Chen C, Hadjipanayis C, Khasraw M, Sun D, Piccioni D,
Sinicrope KD, Campian JL, Kurz SC, Williams B, Smith K,
Tovar-Spinoza Z, Leuthardt EC.
Efficacy
of laser interstitial thermal therapy (LITT) for newly diagnosed
and recurrent IDH
wild-type
glioblastoma.
Neurooncol
Adv. 2022 Apr 6;4(1):vdac040∟.
doi: 10.1093/noajnl/vdac040∟.
PMID: 35611270∟.
Observational study. ˍ
Yan
Z, Zhang X, Hua L, Huang L.
Melatonin
inhibits the malignant progression
of
glioblastoma via regulating miR-16-5p/PIM1.
Curr
Neurovasc Res. 2022 Apr 6∟.
doi: 10.2174/1567202619666220406084947∟.
PMID: 35388757∟.
Laboratory investigation˰ ˍ
Desai
AV, Robinson GW, Gauvain K, Basu EM, Macy ME, Maese L, Whipple NS,
Sabnis AJ, Foster JH, Shusterman S, Yoon J, Weiss BD, Abdelbaki
MS, Armstrong AE, Cash T, Pratilas CA, Corradini N, Marshall LV,
Farid-Kapadia M, Chohan S, Devlin C, Meneses-Lorente G, Cardenas
A, Hutchinson KE, Bergthold G, Caron H, Chow Maneval E, Gajjar A,
Fox E.
Entrectinib
in children and young adults with
solid
or primary CNS tumors harboring NTRK, ROS1 or ALK aberrations
(STARTRK-NG).
Neuro
Oncol. 2022 Apr 8;24(10):1776-1789∟.
doi: 10.1093/neuonc/noac087∟.
PMID: 35395680∟.
Interventional study. ˍ
Han
MH, Kim JM, Cheong JH, Ryu JI, Won YD, Nam GH, Kim CH.
Efficacy
of
Cytokine-Induced
Killer Cell Immunotherapy for Patients With Pathologically Pure
Glioblastoma.
Front
Oncol. 2022 Apr 8;12:851628∟.
doi: 10.3389/fonc.2022.851628∟.
PMID: 35463313∟.
Observational study. ˍ
Nayak
L, Standifer N, Dietrich J, Clarke JL, Dunn GP, Lim M, Cloughesy
T, Gan HK, Flagg E, George E, Gaffey S, Hayden J, Holcroft C, Wen
PY, Macri M, Park AJ, Ricciardi T, Ryan A, Schwarzenberger P,
Venhaus R, de Los Reyes M, Durham NM, Creasy T, Huang RY, Kaley T,
Reardon DA.
Circulating
Immune Cell and Outcome
Analysis
from the Phase 2 Study of PD-L1 Blockade with Durvalumab for Newly
Diagnosed
and Recurrent Glioblastoma.
Clin
Cancer Res. 2022 Apr 8;28(12):2567-2578∟.
doi: 10.1158/1078-0432.CCR-21-4064∟.
PMID: 35395080∟.
Interventional study˰ ˍ
Wang
Y, Pan C, Xie M, Zuo P, Li X, Gu G, Li T, Jiang Z, Wu Z, Zhang J,
Zhang L.
Adult
diffuse intrinsic pontine glioma: clinical, radiological,
pathological,
molecular
features, and treatments of 96 patients.
J
Neurosurg. 2022 Apr 8, 2022:1-11∟.
doi: 10.3171/2022.2.JNS211920∟.
PMID: 35395636∟.
Observational study˰ ˍ
Zhang
L, Wang C, Zeng X.
Risk
Factors for Early Hydrocephalus on Post Unilateral Thalamic Tumor
Resection.
Front
Surg. 2022 Apr 8;9:814308∟.
doi: 10.3389/fsurg.2022.814308∟.
PMID: 35465419∟.
Observational study. ˍ
Rosenberg
T, Yeo KK, Mauguen A, Alexandrescu S, Prabhu SP, Tsai JW,
Malinowski S, Joshirao M, Parikh K, Farouk Sait S, Rosenblum MK,
Benhamida JK, Michaiel G, Tran HN, Dahiya S, Kachurak K, Friedman
GK, Krystal JI, Huang MA, Margol AS, Wright KD, Aguilera D,
MacDonald TJ, Chi SN, Karajannis MA.
Upfront
Molecular
Targeted Therapy for the Treatment of BRAF-Mutant Pediatric
High-Grade
Glioma.
Neuro
Oncol. 2022 Apr 9;24(11):1964-1975∟.
doi: 10.1093/neuonc/noac096∟.
PMID: 35397478∟.
Observational study˰ ˍ
Chen
YW, Lee YY, Lin CF, Huang TY, Ke SH, Mu PF, Pan PS, Chen JK, Lan
TL, Hsu PC, Liang ML, Chen HH, Chang FC, Wu CC, Lin SC, Lee JC,
Chen SK, Liu HM, Peir JJ, Tsai HY, Lin KH, Peng NJ, Chen KH, Wu
YH, Kang YM, Yang WC, Liou SC, Huang WH, Tanaka H, Wong TT, Chao
Y, Chou FI.
Compassionate
Treatment of Brainstem
Tumors
with Boron Neutron Capture Therapy: A Case Series.
Life
(Basel). 2022 Apr 10;12(4):566∟.
doi: 10.3390/life12040566∟.
PMID: 35455057∟.
Case report. ˍ
Choi
HR, Song IA, Oh TK.
Association
between surgical volume and outcomes
after
craniotomy for brain tumor removal: A South Korean nationwide
cohort study.
J
Clin Neurosci. 2022 Apr 12;100:75-81∟.
doi: 10.1016/j.jocn.2022.04.007∟.
PMID: 35427988∟.
Observational study˰ ˍ
Rodriguez
D, Calmon R, Aliaga ES, Warren D, Warmuth-Metz M, Jones C, Mackay
A, Varlet P, Le Deley MC, Hargrave D, Cañete A, Massimino
M, Azizi AA, Saran F, Zahlmann G, Garcia J, Vassal G, Grill J,
Peet A, Dineen RA, Morgan PS, Jaspan T.
MRI
and Molecular Characterization of Pediatric High-Grade Midline
Thalamic
Gliomas:
The HERBY Phase II Trial.
Radiology.
2022 Apr 12;304(1):174-182∟.
doi: 10.1148/radiol.211464∟.
PMID: 35412366∟.
Interventional study˰ ˍ
*
Wang
C, Liu C, Chen J, Jiang H, Zhang W, Yang L, Li X, Li Z, Peng L, Hu
X, Sun P.
Effect
of neoadjuvant iodine-125 brachytherapy upon resection of
glioma.
BMC
Cancer. 2022 Apr 12;22(1):397∟.
doi: 10.1186/s12885-022-09504-5∟.
PMID: 35413858∟.
Observational study. ˍ
Grogan
PT, Deming DA, Helgager J, Ruszkiewicz T, Baskaya MK, Howard SP,
Robins HI.
Entrectinib
demonstrates prolonged efficacy in an adult case of
radiation-refractory NTRK
fusion
glioblastoma.
Neurooncol
Adv. 2022 Apr 13;4(1):vdac046∟.
doi: 10.1093/noajnl/vdac046∟.
PMID: 35673607∟.
Case report. ˍ
*
Han
S, Qu FW, Wang PF, Liu YX, Li SW, Yan CX.
Development
and Validation of a
Nomogram
Model Based on Hematological Indicators for Predicting the
Prognosis of
Diffused
Gliomas.
Front
Surg. 2022 Apr 13;9:803237∟.
doi: 10.3389/fsurg.2022.803237∟.
PMID: 35495765∟.
Observational
study.
ˍ
Pantalone
MR, Rahbar A, Söderberg-Naucler C, Stragliotto
G.
Valganciclovir
as Add-on
to Second-Line Therapy in Patients with Recurrent
Glioblastoma.
Cancers
(Basel). 2022 Apr 13;14(8):1958∟.
doi: 10.3390/cancers14081958∟.
PMID: 35454863∟.
Observational study. ˍ
Sridhar
S, Paul MR, Yeh-Nayre L, Khanna PC, Elster J, Aristizabal P,
Crawford JR.
Single-agent
Bevacizumab in the Treatment of Symptomatic Newly Diagnosed and
Recurrent/Refractory
Pediatric Cervicomedullary Brainstem Low-grade Gliomas: A
Single
Institutional Experience.
J
Pediatr Hematol Oncol. 2022 Apr 13∟.
doi: 10.1097/MPH.0000000000002462∟.
PMID: 35426868∟.
Observational study˰ ˍ
Wang
X, Yu X, Xu H, Wei K, Wang S, Wang Y, Han J.
Serum-derived
extracellular
vesicles
facilitate temozolomide resistance in glioblastoma through a
HOTAIR-dependent mechanism.
Cell
Death Dis. 2022 Apr 13;13(4):344∟.
doi: 10.1038/s41419-022-04699-8∟.
PMID: 35418162∟.
Laboratory investigation. ˍ
Zheng
L, Gong J, Yu T, Zou Y, Zhang M, Nie L, Chen X, Yue Q, Liu Y, Mao
Q, Zhou Q, Chen N.
Diffuse
Midline Gliomas With Histone H3 K27M Mutation in Adults
and
Children: A Retrospective Series of 164 Cases.
Am
J Surg Pathol. 2022 Apr 13∟.
doi: 10.1097/PAS.0000000000001897∟.
PMID: 35416795∟.
Observational study. ˍ
Omuro
A, Brandes AA, Carpentier AF, Idbaih A, Reardon DA, Cloughesy T,
Sumrall A, Baehring J, van den Bent M, Bähr O, Lombardi G,
Mulholland P, Tabatabai G, Lassen U, Sepulveda JM, Khasraw M,
Vauleon E, Muragaki Y, Di Giacomo AM, Butowski N, Roth P, Qian X,
Fu AZ, Liu Y, Potter V, Chalamandaris AG, Tatsuoka K, Lim M,
Weller M.
Radiotherapy
Combined With Nivolumab or
Temozolomide
for Newly Diagnosed Glioblastoma With Unmethylated MGMT Promoter:
An
International Randomized Phase 3 Trial.
Neuro
Oncol. 2022 Apr 14, 2022:noac099∟.
doi: 10.1093/neuonc/noac099∟.
PMID: 35419607∟.
Interventional study. ˍ
*
Lee
J, Grabowski MM, Lathia JD.
Tumor
Treating Fields: killing two birds with
one
stone.
J
Clin Invest. 2022 Apr 15;132(8):e159073∟.
doi: 10.1172/JCI159073∟.
PMID:
35426370∟.
Comment.
ˍ
Refers
to: Chen
D, et al.,Tumor Treating Fields dually activate STING and
AIM2
inflammasomes to induce adjuvant immunity in glioblastoma.
J
Clin Invest. 2022 Feb 24;132(8):e149258∟.
doi: 10.1172/JCI149258∟.
PMID: 35199647∟.
Laboratory investigation.
ˍ